Yujing Tan1, Ruoyang Shao2, Jingyu Li3, Hongyun Huang4, Yanru Wang1, Menglan Zhang1, Jianyun Cao1, Junde Zhang1, Junguo Bu1. 1. Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. 2. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 3. Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. 4. Department of Abdominal Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Abstract
BACKGROUND: Neoadjuvant radiotherapy is a commonly used method for the current standard-of-care for most patients with rectal cancer, when the effects of radioresistance are limited. The phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1), a lipid-metabolism-related gene, has previously been proved to manifest pro-cancer effects in multiple types of cancer. However, whether PITPNC1 plays a role for developing radioresistance in rectal cancer patients is still unknown. Therefore, this study aims to investigate the role of PITPNC1 in rectal cancer radioresistance. METHODS: Patient-derived tissue were used to detect the difference in the expression level of PITPNC1 between radioresistant and radiosensitive patients. Bioinformatic analyses of high-throughput gene expression data were applied to uncover the correlations between PITPNC1 level and oxidative stress. Two rectal cancer cell lines, SW620, and HCT116, were selected in vitro to investigate the effect of PITPNC1 on radioresistance, reactive oxygen species (ROS) generation, apoptosis, and proliferation in rectal cancer. RESULTS: PITPNC1 is highly expressed in radioresistant patient-derived rectal cancer tissues compared to radiosensitive tissue; therefore, PITPNC1 inhibits the generation of ROS and improves the extent of radioresistance of rectal cancer cell lines and then inhibits apoptosis. Knocking down PITPNC1 facilitates the production of ROS while application of the ROS scavenger, N-acetyl-L-cysteine (NAC), could reverse this effect. CONCLUSIONS: PITPNC1 fuels radioresistance of rectal cancer via the inhibition of ROS generation. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Neoadjuvant radiotherapy is a commonly used method for the current standard-of-care for most patients with rectal cancer, when the effects of radioresistance are limited. The phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1), a lipid-metabolism-related gene, has previously been proved to manifest pro-cancer effects in multiple types of cancer. However, whether PITPNC1 plays a role for developing radioresistance in rectal cancer patients is still unknown. Therefore, this study aims to investigate the role of PITPNC1 in rectal cancer radioresistance. METHODS: Patient-derived tissue were used to detect the difference in the expression level of PITPNC1 between radioresistant and radiosensitive patients. Bioinformatic analyses of high-throughput gene expression data were applied to uncover the correlations between PITPNC1 level and oxidative stress. Two rectal cancer cell lines, SW620, and HCT116, were selected in vitro to investigate the effect of PITPNC1 on radioresistance, reactive oxygen species (ROS) generation, apoptosis, and proliferation in rectal cancer. RESULTS: PITPNC1 is highly expressed in radioresistant patient-derived rectal cancer tissues compared to radiosensitive tissue; therefore, PITPNC1 inhibits the generation of ROS and improves the extent of radioresistance of rectal cancer cell lines and then inhibits apoptosis. Knocking down PITPNC1 facilitates the production of ROS while application of the ROS scavenger, N-acetyl-L-cysteine (NAC), could reverse this effect. CONCLUSIONS: PITPNC1 fuels radioresistance of rectal cancer via the inhibition of ROS generation. 2020 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Rectal cancer; oxidative stress; phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1); radioresistance; reactive oxygen species generation (ROS generation)
Authors: Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila Journal: Lancet Oncol Date: 2015-07-14 Impact factor: 41.316
Authors: Li Yu; Yifan Sun; Jingjing Li; Yan Wang; Yuxing Zhu; Yong Shi; Xiaojun Fan; Jianda Zhou; Ying Bao; Jie Xiao; Ke Cao; Peiguo Cao Journal: J Exp Clin Cancer Res Date: 2017-08-15
Authors: Le Tang; Fang Wei; Yingfen Wu; Yi He; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Hao Deng; Ke Cao; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng Journal: J Exp Clin Cancer Res Date: 2018-04-23
Authors: Felix Harpain; Mohamed A Ahmed; Xenia Hudec; Gerald Timelthaler; Gerd Jomrich; Leonhard Müllauer; Edgar Selzer; Wolfgang Dörr; Michael Bergmann; Klaus Holzmann; Bettina Grasl-Kraupp; Michael Grusch; Walter Berger; Brigitte Marian; Gerd R Silberhumer Journal: J Cancer Res Clin Oncol Date: 2018-10-01 Impact factor: 4.553